Stelara (ustekinumab) is an injectable medication used to treat moderate to severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis [1]. Its cost in 2025 and 2026 will be influenced by several factors, including patent expirations, the availability of biosimilars, and market competition.
What are Stelara's expected costs in 2025 and 2026?
Precise cost figures for Stelara in 2025 and 2026 are not yet publicly available, as they are subject to market dynamics and patent exclusivity. However, the introduction of biosimilars is expected to significantly impact pricing.
When does Stelara's patent exclusivity end?
Stelara's U.S. patents are set to expire, paving the way for biosimilar competition. For instance, key patents related to the drug are expected to expire around 2023 and 2024 [2]. This timeline suggests that biosimilar versions could become available in the market in the coming years, potentially leading to price reductions.
How will biosimilars affect Stelara's price?
The entry of biosimilars typically leads to a decrease in the price of the reference biologic drug. Biosimilars are highly similar to their reference products and are approved by regulatory bodies to have no clinically meaningful differences in terms of safety, purity, and potency [3]. This competition often results in more affordable treatment options for patients and healthcare systems.
How does Stelara's cost compare to other biologic treatments?
Stelara is a biologic medication, and its cost is generally comparable to other biologic drugs used for similar conditions, such as TNF inhibitors. However, direct side-by-side cost comparisons are complex and depend on the specific drug, its dosage, the indication, and the negotiated prices by insurance providers. As biosimilars enter the market, the competitive landscape will shift, potentially making Stelara less expensive relative to its competitors.
Which companies are developing biosimilars for Stelara?
Several pharmaceutical companies have been developing biosimilars for Stelara. These include companies like Samsung Bioepis, Celltrion, and Amgen, among others [4]. The approval and market launch dates for these biosimilars will directly influence the competitive pricing of Stelara.
What are the potential risks of Stelara treatment?
Stelara carries potential risks, including serious infections. Patients taking Stelara may be more prone to infections, and healthcare providers monitor for signs of infection during treatment [1]. Other side effects can include upper respiratory infections, headache, fatigue, injection site reactions, and diarrhea.
Can patients access Stelara cost savings programs?
Janssen, the manufacturer of Stelara, typically offers patient assistance programs. These programs can help eligible patients with the cost of their medication. Information on these programs can usually be found on the drug's official website or through healthcare providers.
Sources:
[1] https://www.drugs.com/stelara.html
[2] https://drugpatentwatch.com/blog/2022/12/15/when-does-stelara-ustekinumab-lose-exclusivity-and-face-biosimilar-competition
[3] https://www.fda.gov/vaccines-blood-biologics/biosimilars/understanding-biosimilars
[4] https://drugpatentwatch.com/blog/2022/12/15/when-does-stelara-ustekinumab-lose-exclusivity-and-face-biosimilar-competition